17188-Breast Cancer-NA-1306

Breast Cancer

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

  • Details

ClinicalTrials.gov ID: NCT03725059
Diagnosis Type: NA
USOR Number:

  • Address

8196 Walnut Hill Lane, Suite 100
Dallas, TX 75231
P: (214) 345-7394

Search by practice name, trial titles, indicators and specific disease types.